Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.43) by 5.09 percent. This is a 33.87 percent increase over losses of $(0.62) per share from the same period last year.